C. Paul

28.7k total citations · 7 hit papers
420 papers, 16.5k citations indexed

About

C. Paul is a scholar working on Immunology, Dermatology and Immunology and Allergy. According to data from OpenAlex, C. Paul has authored 420 papers receiving a total of 16.5k indexed citations (citations by other indexed papers that have themselves been cited), including 218 papers in Immunology, 214 papers in Dermatology and 60 papers in Immunology and Allergy. Recurrent topics in C. Paul's work include Psoriasis: Treatment and Pathogenesis (179 papers), Dermatology and Skin Diseases (161 papers) and Allergic Rhinitis and Sensitization (48 papers). C. Paul is often cited by papers focused on Psoriasis: Treatment and Pathogenesis (179 papers), Dermatology and Skin Diseases (161 papers) and Allergic Rhinitis and Sensitization (48 papers). C. Paul collaborates with scholars based in France, United States and Germany. C. Paul's co-authors include Kristian Reich, Kim Papp, F. Aubin, D. Jullien, Michel Le Maître, P. Joly, S. Aractingi, Mark Lebwohl, B. Cribier and L. Misery and has published in prestigious journals such as Science, New England Journal of Medicine and The Lancet.

In The Last Decade

C. Paul

383 papers receiving 16.0k citations

Hit Papers

Comparison of ixekizumab with etanercept or placebo in mo... 2014 2026 2018 2022 2015 2014 2016 2021 2021 200 400 600
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Comparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis (UNCOVER-2 and UNCOVER-3): results from two phase 3 randomised trials
    2015 658 citations C.E.M. Griffiths, Kristian Reich et al. profile →
  2. Patient perspectives in the management of psoriasis: Results from the population-based Multinational Assessment of Psoriasis and Psoriatic Arthritis Survey
    2014 411 citations Mark Lebwohl, H. Bachelez et al. profile →
  3. A prospective phase III, randomized, double‐blind, placebo‐controlled study of brodalumab in patients with moderate‐to‐severe plaque psoriasis
    2016 376 citations Kim Papp, Kristian Reich et al. British Journal of Dermatology profile →
  4. Abrocitinib versus Placebo or Dupilumab for Atopic Dermatitis
    2021 287 citations Diamant Thaçi, C. Paul et al. profile →
  5. Bimekizumab versus Secukinumab in Plaque Psoriasis
    2021 230 citations Kristian Reich, Richard B. Warren et al. profile →
  6. Deucravacitinib versus placebo and apremilast in moderate to severe plaque psoriasis: Efficacy and safety results from the 52-week, randomized, double-blinded, phase 3 Program fOr Evaluation of TYK2 inhibitor psoriasis second trial
    2022 173 citations Bruce Strober, Diamant Thaçi et al. profile →
  7. Trial of Nemolizumab in Moderate-to-Severe Prurigo Nodularis
    2020 173 citations C. Paul, L. Misery et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
C. Paul France 68 8.8k 8.8k 3.0k 2.7k 2.0k 420 16.5k
A.Y. Finlay United Kingdom 70 6.7k 0.8× 15.1k 1.7× 2.3k 0.8× 4.6k 1.7× 1.8k 0.9× 273 22.5k
L. Puig Spain 57 11.2k 1.3× 7.7k 0.9× 3.8k 1.3× 1.1k 0.4× 2.2k 1.1× 626 18.2k
Giampiero Girolomoni Italy 81 12.5k 1.4× 9.9k 1.1× 3.7k 1.2× 3.8k 1.4× 2.0k 1.0× 558 23.7k
Richard G. Langley Canada 67 14.7k 1.7× 9.6k 1.1× 3.4k 1.1× 1.2k 0.4× 2.7k 1.3× 264 19.1k
John Koo United States 55 8.0k 0.9× 6.8k 0.8× 1.7k 0.6× 1.0k 0.4× 1.4k 0.7× 339 12.5k
Wolf‐­Henning Boehncke Germany 55 8.7k 1.0× 4.4k 0.5× 2.7k 0.9× 917 0.3× 1.3k 0.6× 356 13.2k
Kristian Reich Germany 80 20.2k 2.3× 14.0k 1.6× 5.0k 1.7× 2.3k 0.8× 3.7k 1.8× 497 26.2k
Alan Menter United States 80 19.1k 2.2× 12.2k 1.4× 4.7k 1.6× 1.3k 0.5× 3.5k 1.7× 387 25.4k
Ulrich Mrowietz Germany 60 7.5k 0.9× 5.9k 0.7× 1.4k 0.5× 719 0.3× 1.5k 0.7× 331 12.7k
Werner J. Pichler Switzerland 76 5.0k 0.6× 5.8k 0.7× 5.2k 1.7× 4.8k 1.7× 2.3k 1.2× 366 20.1k

Countries citing papers authored by C. Paul

Since Specialization
Citations

This map shows the geographic impact of C. Paul's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by C. Paul with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites C. Paul more than expected).

Fields of papers citing papers by C. Paul

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by C. Paul. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by C. Paul. The network helps show where C. Paul may publish in the future.

Co-authorship network of co-authors of C. Paul

This figure shows the co-authorship network connecting the top 25 collaborators of C. Paul. A scholar is included among the top collaborators of C. Paul based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with C. Paul. C. Paul is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Lebwohl, Mark, Richard B. Warren, Howard Sofen, et al.. (2024). Deucravacitinib in plaque psoriasis: 2-year safety and efficacy results from the phase III POETYK trials. British Journal of Dermatology. 190(5). 668–679. 35 indexed citations
2.
Lebwohl, Mark, Richard B. Warren, Howard Sofen, et al.. (2023). Deucravacitinib long-term efficacy with continuous treatment in plaque psoriasis: 2-year results from the phase 3 POETYK PSO program. SKIN The Journal of Cutaneous Medicine. 7(2). s118–s118. 3 indexed citations
3.
Schäkel, Knut, Kristian Reich, K. Asadullah, et al.. (2023). Early disease intervention with guselkumab in psoriasis leads to a higher rate of stable complete skin clearance (‘clinical super response’): Week 28 results from the ongoing phase IIIb randomized, double‐blind, parallel‐group, GUIDE study. Journal of the European Academy of Dermatology and Venereology. 37(10). 2016–2027. 46 indexed citations
4.
Mahé, E., M.‐A. Richard, Yann De Rycke, et al.. (2023). Impact of the first wave of the COVID-19 pandemic on the treatment of psoriasis with systemic therapies in France: Results from the PSOBIOTEQ cohort. Annales de Dermatologie et de Vénéréologie. 150(2). 101–108. 1 indexed citations
5.
Pinter, Andreas, Antonio Costanzo, Sanjay Khattri, et al.. (2023). Comparative Effectiveness and Durability of Biologics in Clinical Practice: Month 12 Outcomes from the International, Observational Psoriasis Study of Health Outcomes (PSoHO). Dermatology and Therapy. 14(6). 1479–1493. 8 indexed citations
6.
Strober, Bruce, Yayoi Tada, Ulrich Mrowietz, et al.. (2023). Bimekizumab maintenance of response through 3 years in patients with moderate-to-severe plaque psoriasis: results from the BE BRIGHT open-label extension trial. British Journal of Dermatology. 188(6). 749–759. 19 indexed citations
7.
Mahé, E., M.‐A. Richard, Yann De Rycke, et al.. (2021). Impact de l’épidémie de COVID-19 lors de la 1ère vague sur les patients de la cohorte PSOBIOTEQ traités pour psoriasis cutané. PubMed Central. 1(8). A298–A299. 1 indexed citations
8.
Livideanu, C. Bulaï, P.A. Apoil, Benoît Lepage, et al.. (2021). Apport de la cytométrie de flux médullaire pour le diagnostic de mastocytose systémique. 1(8). A144–A145.
9.
Blauvelt, Andrew, C. Paul, P.C.M. van de Kerkhof, et al.. (2020). Long‐term safety of certolizumab pegol in plaque psoriasis: pooled analysis over 3 years from three phase III, randomized, placebo‐controlled studies. British Journal of Dermatology. 184(4). 640–651. 15 indexed citations
10.
Luger, Thomas A., Matthias Augustin, Julien Lambert, et al.. (2020). Unmet medical needs in the treatment of atopic dermatitis in infants: An Expert consensus on safety and efficacy of pimecrolimus. Pediatric Allergy and Immunology. 32(3). 414–424. 9 indexed citations
11.
Papp, Kim, C. Leonardi, Andrew Blauvelt, et al.. (2017). Ixekizumab treatment for psoriasis: integrated efficacy analysis of three double-blinded, controlled studies (UNCOVER-1, UNCOVER-2, UNCOVER-3). British Journal of Dermatology. 178(3). 674–681. 77 indexed citations
12.
Brenaut, E., C. Horreau, Claire Pouplard, et al.. (2013). Alcohol consumption and psoriasis: a systematic literature review. Journal of the European Academy of Dermatology and Venereology. 27(s3). 30–35. 118 indexed citations
13.
Annereau, Jean‐Philippe, Nicolas Guilbaud, I. Garrido, et al.. (2012). CD10 expression by melanoma cells is associated with aggressive behavior in vitro and predicts rapid metastatic progression in humans. Journal of Dermatological Science. 69(2). 105–113. 17 indexed citations
14.
Paul, C., J.F. Stalder, Diamant Thaçi, et al.. (2011). Patient satisfaction with injection devices: a randomized controlled study comparing two different etanercept delivery systems in moderate to severe psoriasis. Journal of the European Academy of Dermatology and Venereology. 26(4). 448–455. 22 indexed citations
15.
Ammoury, Alfred, et al.. (2009). Moderate to severe psoriasis: from topical to biological treatment. Journal of the European Academy of Dermatology and Venereology. 23(11). 1324–1326. 14 indexed citations
16.
Kaoukhov, Alexandre, et al.. (2008). Tolérance rénale de la ciclosporine au long cours dans le psoriasis. Annales de Dermatologie et de Vénéréologie. 127(2). 180–183.
17.
Paul, C., et al.. (2000). Multiple subungual hemorrhages as a manifestation of Sweet’s syndrome. European Journal of Dermatology. 7(2). 121–122. 1 indexed citations
18.
Paul, C. & Vincent Ho. (1998). Ascomycins in dermatology. Seminars in Cutaneous Medicine and Surgery. 17(4). 256–259. 18 indexed citations
19.
Paul, C., et al.. (1997). [BCG-induced mycobacterium infection induced by alternative medicine].. PubMed. 124(10). 710–2. 7 indexed citations
20.
Paul, C.. (1986). Le cabinet de physique du Séminaire de Québec. Érudit (Université de Montréal). 1(4). 37–39.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by A.Y. Finlay Breakdown of academic impact, for papers by L. Puig Breakdown of academic impact, for papers by Giampiero Girolomoni Breakdown of academic impact, for papers by Richard G. Langley Breakdown of academic impact, for papers by John Koo Breakdown of academic impact, for papers by Wolf‐­Henning Boehncke Breakdown of academic impact, for papers by Kristian Reich Breakdown of academic impact, for papers by Alan Menter Breakdown of academic impact, for papers by Ulrich Mrowietz Breakdown of academic impact, for papers by Werner J. Pichler
Rankless by CCL
2026